Asia Pacific Anaphylaxis Treatment Market is expected to reach US$ 664.0 Mn by 2028


PRESS RELEASE BY The Insight Partners 26 Jul 2021

Share this press on


Epinephrine Segment has the Largest Share of Medication Type in the Asia Pacific Anaphylaxis Treatment Market during 2021–2028

According to The Insight Partners market research study on “Asia Pacific Anaphylaxis Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Medication Type, Route of Administration, Allergy Type, and Distribution Channel,” is expected to reach US$ 664.0 million by 2028 from US$ 350.7 million in 2021. The market is estimated to grow at a CAGR of 9.6% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific anaphylaxis treatment market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising incidence of anaphylaxis and recent approvals of epinephrine are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the poor accessibility to epinephrine auto-injectors in low-income countries.

Certainly, COVID-19 increases the risk of aggravating asthma and allergic diseases, but the government and private agencies are guiding for the treatments. According to guidelines of the Korean Academy of Asthma, Allergy and Clinical Immunology, and the Korean Academy of Pediatric Allergy and Respiratory Disease, detailed monitoring and optimal treatment with AIT, ICS, and biologics need to be continued in all patients who have asthma and allergic diseases. This can be achieved in a safe condition using optimal protective measures. Patients at high risk (older age and comorbid conditions) should be monitored more strictly. All the allergy/immunology specialists who strive to stay up for optimal health protection by focusing on patient management during the COVID-19 pandemic are necessary. As APAC passes through these challenging times of the COVID-19 pandemic, The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) as an allergy/immunology community via its COVID-19 Task Force is carefully monitoring and updating Food and Drug Administration/Centers for Disease Control and Prevention/ WHO and other crucial scientific information on COVID-19 on its website COVID-19 resource section. Thus, the rising need for allergy treatment is likely to boost the market.

The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel. Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others. In 2020, epinephrine segment accounted for the highest share of the market. The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children. Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.

Amneal Pharmaceuticals Inc., Mylan N.V., Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., and ALK-ABELLó are among the leading companies in the Asia Pacific anaphylaxis treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in December 2020, GSK Consumer Healthcare launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerin. The daily usage of the nasal spray washes out the allergens, pollutants, and debris that are trapped in the nasal passage, helping in the removal of allergy symptoms, and thus maintaining nasal hygiene. 

The report segments the Asia Pacific Anaphylaxis Treatment market as follows:

By Medication Type

  • Epinephrine
  • Antihistamines
  • Steroids
  • Beta-Agonist
  • Others

By Route of Administration

  • Parenteral
  • Oral
  • Others

By Allergy Type

  • Food Allergy
  • Medications
  • Insect Stings
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Country

  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure